PredictCan Biotechnologies
PredictCan Biotechnologies is a startup dedicated to advancing precision medicine in oncology through innovative cell educating technology. They develop state-of-the-art 3D models for early cancer detection, drug discovery, safety, and efficacy, aiming to support personalized patient care and improve clinical outcomes.
Industries
Nr. of Employees
small (1-50)
PredictCan Biotechnologies
Biopôle Euromédecine, 1682 Rue de la Valsière, 34790 Grabels FRANCE
Products
Patient‑centric spheroid model platform for R&D
A platform of standardized, cell line–based spheroid assays whose phenotype is modulated by subject-derived inputs to produce patient- and healthy-representative cohorts for toxicity, efficacy and biomarker research.
One-step immune cell differentiation medium (ready-to-use)
A ready-to-use medium and protocol for single-step differentiation of monocytes or PBMCs into activated macrophage and dendritic cell populations suitable for functional assays.
Patient‑centric spheroid model platform for R&D
A platform of standardized, cell line–based spheroid assays whose phenotype is modulated by subject-derived inputs to produce patient- and healthy-representative cohorts for toxicity, efficacy and biomarker research.
One-step immune cell differentiation medium (ready-to-use)
A ready-to-use medium and protocol for single-step differentiation of monocytes or PBMCs into activated macrophage and dendritic cell populations suitable for functional assays.
Services
Project-based engagement to apply individualized 3D model platforms for drug safety (DILI/iDILI) and efficacy assessment, phenotypic screening, and immunotherapy evaluation; includes cohort assembly and translational benchmarking against clinical outcomes.
Project-based engagement to apply individualized 3D model platforms for drug safety (DILI/iDILI) and efficacy assessment, phenotypic screening, and immunotherapy evaluation; includes cohort assembly and translational benchmarking against clinical outcomes.
Expertise Areas
- Patient‑centric in vitro model development
- Phenotypic drug discovery and HTS workflows
- Predictive toxicology for DILI and idiosyncratic DILI
- Preclinical efficacy testing for oncology
Key Technologies
- 3D multicellular spheroid models
- Subject-dependent phenotype induction (cell educating protocols)
- Patient‑cohort in vitro panels
- High-throughput screening (HTS) compatibility
News & Updates
Publication on using cell educating technology for cancer microenvironment modeling.
Partnership to develop new solutions reducing animal testing in research.
Participation in Copenhagen, presentation on immune-mediated drug-induced liver injury.
Joining as a bronze-level member to promote reduction, refinement, and replacement of animal testing.
Research on detecting immune-mediated idiosyncratic DILI using spheroid models.
Modeling microenvironment phenotype for drug efficacy evaluation.
Publication on using cell educating technology for cancer microenvironment modeling.
Partnership to develop new solutions reducing animal testing in research.
Participation in Copenhagen, presentation on immune-mediated drug-induced liver injury.
Joining as a bronze-level member to promote reduction, refinement, and replacement of animal testing.
Research on detecting immune-mediated idiosyncratic DILI using spheroid models.
Modeling microenvironment phenotype for drug efficacy evaluation.